(Oslo, February 3, 2026) - Medistim ASA (OSE: MEDI), a leading niche provider of
ultrasound technology headquartered in Oslo, Norway, today announced the
establishment of a direct sales operation in Japan, effective March 16, 2026. 
Medistim develops and commercializes advanced medical equipment for use in
cardiac, vascular, and transplant surgery. The expansion into a direct sales
model in Japan is intended to strengthen the company's market presence and
enhance customer engagement in one of its key strategic markets.  This
initiative underscores Medistim's continued commitment to delivering
high-quality service and clinical support to cardiovascular surgeons globally
and aligns with the Company's long-term global growth strategy.

Medistim maintains a very strong market position in Japan, where approximately
90% of the estimated 17,000 annual coronary artery bypass graft (CABG)
procedures are supported by the company's Transit Time Flow Measurement (TTFM)
technology.

Future growth in the Japanese market is expected to be driven by continued
conversion from installed base systems utilizing TTFM-only functionality to
next-generation platforms integrating both TTFM and High-Frequency Ultrasound
(HFUS). This represents a meaningful value-enhancement opportunity within the
existing customer base.

In addition, the vascular surgery segment presents significant incremental
growth potential, supported by untapped procedural volumes and broader clinical
adoption of Medistim's technology portfolio.

"We are pleased to announce this strategic initiative, which will further
strengthen our engagement with customers in Japan," said Kari E. Krogstad,
President and CEO of Medistim ASA. "The establishment of a direct presence in
Japan has been under evaluation for some time, and we have now resolved to
proceed. We are well prepared for this transition, with key personnel for the
new subsidiary already in place.

Our experience from other markets demonstrates that a direct operating model
enhances customer proximity, supports sustainable revenue growth, and
contributes positively to margins, while ensuring the highest standards of
service and clinical support. We are confident that this step will reinforce our
market position and unlock additional growth opportunities in Japan.

At the same time, we would like to acknowledge our long-standing distribution
partner, Nippon BXI K.K., for more than three decades of collaboration and for
their significant contribution to expanding Medistim's presence in the Japanese
market. We will work closely together to secure a seamless transition ahead of
the conclusion of the distribution agreement on March 16, 2026."

The newly established operating subsidiary, Medistim Japan K.K., is a Japanese
corporation wholly owned by Medistim ASA. The company is headquartered in
Minato, Tokyo, and will serve as the platform for Medistim's direct commercial
operations in the Japanese market.

About Medistim:
Medistim was established in 1984 and has a track record of profitable growth
over the past 20 years. The company is a pioneer within its segment and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Canada, China, Germany, UK,
Spain, Denmark, Sweden and Norway, in addition to around 60 distributors in
Europe, Asia, Middle East, Africa, and South America.  Medistim is listed on the
Oslo stock exchange under the ticker OSE:MEDI.
For more information, visit the Medistim home page:  www.medistim.com 
For more information, contact: 

President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110  
Email: kari.krogstad@medistim.com 

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940  
Email: thomas.jakobsen@medistim.com